Led · Seed · Jun 2025

LiveDrop builds a software-based solution that enables fast, secure, unidirectional offline data transfer via optical encoding on standard hardware such as laptops, smartphones, and cameras. The technology is designed for seamless integration into mission systems and existing software environments, removing the need for wireless or network-based communication. LiveDrop focuses primarily on the Defense & Security sector while pursuing a dual-use strategy with potential applications in cybersecurity, healthcare, and secure end-user devices. The company was founded in 2021 in Eindhoven and currently has a twelve-person team. With an oversubscribed $2.5 million seed round closed, LiveDrop plans to scale its technology across defense, government, and civilian sectors and accelerate international deployment and deeper integration into secure data ecosystems. Investors are also expected to provide strategic guidance and market access to support deployment in NATO countries and beyond.

Participated · Equity · May 2025

Optics11 builds advanced fiber-optic sensing platforms capable of detecting ultra-sensitive vibration and acoustic signals in harsh environments such as deep-sea installations and high-voltage grids. By “listening with light,” the systems identify subtle signatures well before they escalate into outages or security incidents, giving operators critical time to assess risks and coordinate responses. The company positions its technology as increasingly vital amid growing European concern over disruptions to subsea cables, pipelines, maritime trade routes, and electricity networks. Optics11’s solutions target infrastructure that is most vulnerable, offering early warning for both civilian and defense applications. The firm describes itself as a leader in fiber-optic sensing for protecting sea lanes, offshore assets, and energy supply chains. With fresh capital, Optics11 plans to accelerate productization, ramp up R&D, and broaden adoption of its platforms across Europe. While specific operating metrics such as revenue or user numbers were not disclosed, the company emphasizes its strategic role in bolstering Europe’s energy resilience and security.

Participated · Seed · May 2025

CryoCloud provides a cryo-electron microscopy (cryo-EM) SaaS platform that enables researchers to visualise and analyse protein structures at high resolution. The platform automates complex structural biology workflows and gives scientists access to petabytes of storage and dozens of GPUs in minutes rather than months. It uses proprietary machine-learning algorithms to process terabytes of structural data and reduce the time and cost of molecular imaging. CryoCloud aims to make cryo-EM more accessible by lowering hardware and expertise barriers and supporting structure-based drug discovery. The company plans to use the new funding to build the next generation of algorithms and expand its platform capabilities. The €2M Seed round brings total investment to €2.8M following a €500,000 Pre-Seed in 2023. Customers report higher productivity, and the customer base spans more than 25 countries across academia, biotech, and the pharmaceutical industry. CryoCloud provides a cloud-based cryoEM data analysis platform that enables fast, scalable determination of 3D protein structures for drug discovery. Co-founded in 2021 and based in Utrecht, the Netherlands, the company progressed from conceptual stages through various accelerator programs to launch its analysis platform. The platform allows scientists to determine protein structures experimentally and visualize relevant targets in their native or drug-bound state. CryoCloud has moved beyond concept to a launched product and recently closed external financing. It raised €500k in a pre-seed round led by Nina Capital with participation from Utrecht Health Seed Fund and ROM Utrecht Region. The company will use the funds to expand the capabilities of its platform.

Led · Equity · Apr 2023

Delmic produces correlative light and electron microscopy solutions and user-friendly tools designed to help researchers and companies obtain nanoscale insights quickly. Its product lineup includes the SECOM correlative system, the SPARC Spectral cathodoluminescence detector, CRYO solutions for contamination-free cryo-ET workflows, a Cathodoluminescence portfolio for optical-property analysis, and a Fast Imaging division for high-volume data. The company was founded in 2010 and its early work involved collaborations with the Charged Particle Optics group at Delft University of Technology and the NWO-Institute AMOLF. Delmic aims to automate the complete microscopy process to make microscopy more approachable and to drastically lower the cost per sample, broadening access to nanostructural data. Its solutions are used across life-science and material-science research, and the company plans to scale service, sales, and application activities globally. Delmic recently secured financing to support product development, automation efforts, and wider commercial rollout.

Participated · Equity · Sep 2022

Founded in 2011 in Amsterdam, Optics11 Life builds a portfolio of mechanobiology tools—Pavone, Piuma, Chiaro, and Cuore—that perform high-throughput nano-indentation and 3D contractility measurements on cells, tissues, and biomaterials. The company combines fibre-optic sensing with automation and imaging to generate data that improve drug development workflows, enable disease modelling, and support quality control in regenerative medicine. Its technology also underpins New Approach Methodologies (NAMs) aimed at reducing or eliminating animal testing. With a team of more than 60 employees, Optics11 Life serves academic and commercial laboratories in the US, Europe, and Asia. The newly secured capital will be channelled into further instrument development, an expanded global sales footprint, and a broader product roadmap. Management positions the company to help customers create accessible, affordable, and effective therapies while decreasing reliance on animal models. No revenue or user figures were disclosed in the article.